Travere Therapeutics, Inc.

SEC 4 · Filed

0001698262-26-000002Accepted

Applies to the EDGAR acceptance time.

Other time zone
Insider transactionsEvent date Apr 13, 2026

Grant, award or other acquisition by ROTE WILLIAM E.

Security
Common Stock
Code
A
Shares
14,000
Price per share
0.00
Structured facts
{
  "code": "A",
  "date": "2026-04-13",
  "direction": "A",
  "exercise_price": null,
  "expiration": null,
  "footnotes": {
    "F1": "On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer\u0027s confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS."
  },
  "owners": [
    {
      "cik": "0001698262",
      "name": "ROTE WILLIAM E.",
      "roles": [
        "officer"
      ],
      "title": "Chief Research Officer"
    }
  ],
  "ownership": "D",
  "post_shares": "123087",
  "price": "0",
  "row": 1,
  "rule_10b5_1": "1",
  "security": "Common Stock",
  "shares": "14000",
  "table": "I",
  "underlying_security": null,
  "underlying_shares": null
}